Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: Common types of shorter transcripts are true alternative splice variants

Kay Uwe Wagner, Patricia Dierisseau, Edmund B. Rucker, Gertraud W. Robinson, Lothar Hennighausen

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The functional inactivation of the tumor susceptibility gene tsg101 in mouse NIH3T3 cells leads to cell transformation and the formation of metastatic tumors in nude mice. We cloned, mapped and sequenced the mouse tsg101 gene and further identified a processed pseudogene that is 98% identical to the tsg101, cDNA. Based on Northern blot analysis, tsg101 is expressed ubiquitously in mouse tissues. A comparison of the coding region of the mouse tsg101 gene with the human TSG101 cDNA revealed that both the mouse and human gene encode ten additional highly conserved amino acids at the N-terminus. Based on the mouse tsg101 genomic structure, we predicted four additional introns within the human TSG101 gene. Their location was confirmed using PCR and sequencing analysis. The presence of these so far unidentified introns now explains published data on aberrantly spliced mRNA products that were frequently observed in primary breast tumors. We show that a majority of shorter TSG101 transcripts are not the result of aberrant splicing events, but represent a fraction of true alternative splice variants. Finally, we examined tsg101 expression patterns during different stages of mammary gland development and in different transgenic mouse models for breast tumorigenesis.

Original languageEnglish (US)
Pages (from-to)2761-2770
Number of pages10
JournalOncogene
Volume17
Issue number21
DOIs
StatePublished - Nov 26 1998

Fingerprint

Transcriptional Activation
Genes
Neoplasms
Introns
Complementary DNA
Pseudogenes
Human Mammary Glands
Nude Mice
Northern Blotting
Transgenic Mice
Carcinogenesis
Breast
Breast Neoplasms
Amino Acids
Polymerase Chain Reaction
Messenger RNA

Keywords

  • Genomic DNA
  • Human
  • Mammary gland
  • Mice
  • Pseudogene
  • TSG101 protein

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101 : Common types of shorter transcripts are true alternative splice variants. / Wagner, Kay Uwe; Dierisseau, Patricia; Rucker, Edmund B.; Robinson, Gertraud W.; Hennighausen, Lothar.

In: Oncogene, Vol. 17, No. 21, 26.11.1998, p. 2761-2770.

Research output: Contribution to journalArticle

Wagner, Kay Uwe ; Dierisseau, Patricia ; Rucker, Edmund B. ; Robinson, Gertraud W. ; Hennighausen, Lothar. / Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101 : Common types of shorter transcripts are true alternative splice variants. In: Oncogene. 1998 ; Vol. 17, No. 21. pp. 2761-2770.
@article{fbba5d4b501242db911690964f6fc082,
title = "Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: Common types of shorter transcripts are true alternative splice variants",
abstract = "The functional inactivation of the tumor susceptibility gene tsg101 in mouse NIH3T3 cells leads to cell transformation and the formation of metastatic tumors in nude mice. We cloned, mapped and sequenced the mouse tsg101 gene and further identified a processed pseudogene that is 98{\%} identical to the tsg101, cDNA. Based on Northern blot analysis, tsg101 is expressed ubiquitously in mouse tissues. A comparison of the coding region of the mouse tsg101 gene with the human TSG101 cDNA revealed that both the mouse and human gene encode ten additional highly conserved amino acids at the N-terminus. Based on the mouse tsg101 genomic structure, we predicted four additional introns within the human TSG101 gene. Their location was confirmed using PCR and sequencing analysis. The presence of these so far unidentified introns now explains published data on aberrantly spliced mRNA products that were frequently observed in primary breast tumors. We show that a majority of shorter TSG101 transcripts are not the result of aberrant splicing events, but represent a fraction of true alternative splice variants. Finally, we examined tsg101 expression patterns during different stages of mammary gland development and in different transgenic mouse models for breast tumorigenesis.",
keywords = "Genomic DNA, Human, Mammary gland, Mice, Pseudogene, TSG101 protein",
author = "Wagner, {Kay Uwe} and Patricia Dierisseau and Rucker, {Edmund B.} and Robinson, {Gertraud W.} and Lothar Hennighausen",
year = "1998",
month = "11",
day = "26",
doi = "10.1038/sj.onc.1202529",
language = "English (US)",
volume = "17",
pages = "2761--2770",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "21",

}

TY - JOUR

T1 - Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101

T2 - Common types of shorter transcripts are true alternative splice variants

AU - Wagner, Kay Uwe

AU - Dierisseau, Patricia

AU - Rucker, Edmund B.

AU - Robinson, Gertraud W.

AU - Hennighausen, Lothar

PY - 1998/11/26

Y1 - 1998/11/26

N2 - The functional inactivation of the tumor susceptibility gene tsg101 in mouse NIH3T3 cells leads to cell transformation and the formation of metastatic tumors in nude mice. We cloned, mapped and sequenced the mouse tsg101 gene and further identified a processed pseudogene that is 98% identical to the tsg101, cDNA. Based on Northern blot analysis, tsg101 is expressed ubiquitously in mouse tissues. A comparison of the coding region of the mouse tsg101 gene with the human TSG101 cDNA revealed that both the mouse and human gene encode ten additional highly conserved amino acids at the N-terminus. Based on the mouse tsg101 genomic structure, we predicted four additional introns within the human TSG101 gene. Their location was confirmed using PCR and sequencing analysis. The presence of these so far unidentified introns now explains published data on aberrantly spliced mRNA products that were frequently observed in primary breast tumors. We show that a majority of shorter TSG101 transcripts are not the result of aberrant splicing events, but represent a fraction of true alternative splice variants. Finally, we examined tsg101 expression patterns during different stages of mammary gland development and in different transgenic mouse models for breast tumorigenesis.

AB - The functional inactivation of the tumor susceptibility gene tsg101 in mouse NIH3T3 cells leads to cell transformation and the formation of metastatic tumors in nude mice. We cloned, mapped and sequenced the mouse tsg101 gene and further identified a processed pseudogene that is 98% identical to the tsg101, cDNA. Based on Northern blot analysis, tsg101 is expressed ubiquitously in mouse tissues. A comparison of the coding region of the mouse tsg101 gene with the human TSG101 cDNA revealed that both the mouse and human gene encode ten additional highly conserved amino acids at the N-terminus. Based on the mouse tsg101 genomic structure, we predicted four additional introns within the human TSG101 gene. Their location was confirmed using PCR and sequencing analysis. The presence of these so far unidentified introns now explains published data on aberrantly spliced mRNA products that were frequently observed in primary breast tumors. We show that a majority of shorter TSG101 transcripts are not the result of aberrant splicing events, but represent a fraction of true alternative splice variants. Finally, we examined tsg101 expression patterns during different stages of mammary gland development and in different transgenic mouse models for breast tumorigenesis.

KW - Genomic DNA

KW - Human

KW - Mammary gland

KW - Mice

KW - Pseudogene

KW - TSG101 protein

UR - http://www.scopus.com/inward/record.url?scp=0032569885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032569885&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1202529

DO - 10.1038/sj.onc.1202529

M3 - Article

C2 - 9840940

AN - SCOPUS:0032569885

VL - 17

SP - 2761

EP - 2770

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 21

ER -